{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:36:04Z","timestamp":1794836164149,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016042"],"award-info":[{"award-number":["P30CA016042"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","award":["Lolkema\/NL-72-RG-11"],"award-info":[{"award-number":["Lolkema\/NL-72-RG-11"]}],"id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","award":["212082PCR3014"],"award-info":[{"award-number":["212082PCR3014"]}],"id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomic landscape. With the recent development of novel treatments, accurate stratification strategies are needed. Here we present the whole-genome sequencing (WGS) analysis of fresh-frozen metastatic biopsies from 197 mCRPC patients. Using unsupervised clustering based on genomic features, we define eight distinct genomic clusters. We observe potentially clinically relevant genotypes, including microsatellite instability (MSI), homologous recombination deficiency (HRD) enriched with genomic deletions and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    aberrations, a tandem duplication genotype associated with\n                    <jats:italic>CDK12<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    and a chromothripsis-enriched subgroup. Our data suggests that stratification on WGS characteristics may improve identification of MSI,\n                    <jats:italic>CDK12<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    and HRD patients. From WGS and ChIP-seq data, we show the potential relevance of recurrent alterations in non-coding regions identified with WGS and highlight the central role of AR signaling in tumor progression. These data underline the potential value of using WGS to accurately stratify mCRPC patients into clinically actionable subgroups.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-13084-7","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T06:04:02Z","timestamp":1574229842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":191,"title":["The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact"],"prefix":"10.1038","volume":"10","author":[{"given":"Lisanne F.","family":"van Dessel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job","family":"van Riet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minke","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi N.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8424-3768","authenticated-orcid":false,"given":"Julie","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-7520","authenticated-orcid":false,"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-3366","authenticated-orcid":false,"given":"John W. M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Cuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-1477","authenticated-orcid":false,"given":"Harmen J. G.","family":"van de Werken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-1831","authenticated-orcid":false,"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-2928","authenticated-orcid":false,"given":"Martijn P.","family":"Lolkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"issue":"11","key":"13084_CR1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrurol.2012.185","volume":"9","author":"Lara K. Boyd","year":"2012","unstructured":"Boyd, L. K., Mao, X. & Lu, Y. J. The complexity of prostate cancer: genomic alterations and heterogeneity. Nature Rev. Urol. (2012). https:\/\/doi.org\/10.1038\/nrurol.2012.185","journal-title":"Nature Reviews Urology"},{"issue":"2","key":"13084_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","volume":"71","author":"Lei Wei","year":"2017","unstructured":"Wei, L. et al. Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators. Eur. Urol. (2017). https:\/\/doi.org\/10.1016\/j.eururo.2016.07.008","journal-title":"European Urology"},{"issue":"3","key":"13084_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MOU.0000000000000278","volume":"26","author":"Stephanie A. Mullane","year":"2016","unstructured":"Mullane, S. A. & Van Allen, E. M. Precision medicine for advanced prostate cancer. Curr. Opin. Urol. (2016). https:\/\/doi.org\/10.1097\/MOU.0000000000000278","journal-title":"Current Opinion in Urology"},{"key":"13084_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ctrv.2017.02.001","volume":"54","author":"Chiara Ciccarese","year":"2017","unstructured":"Ciccarese, C. et al. Prostate cancer heterogeneity: discovering novel molecular targets for therapy. Cancer Treatment Rev. (2017). https:\/\/doi.org\/10.1016\/j.ctrv.2017.02.001","journal-title":"Cancer Treatment Reviews"},{"key":"13084_CR5","doi-asserted-by":"publisher","unstructured":"Shtivelman, E., Beer, T. M. & Evans, C. P. Molecular pathways and targets in prostate cancer. Oncotarget (2014). https:\/\/doi.org\/10.18632\/oncotarget.2406","DOI":"10.18632\/oncotarget.2406"},{"key":"13084_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"issue":"12","key":"13084_CR7","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/cncr.29927","volume":"122","author":"Helen Chow","year":"2016","unstructured":"Chow, H. et al. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer (2016). https:\/\/doi.org\/10.1002\/cncr.29927","journal-title":"Cancer"},{"issue":"7","key":"13084_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","volume":"19","author":"Noel Clarke","year":"2018","unstructured":"Clarke, N. et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. (2018). https:\/\/doi.org\/10.1016\/S1470-2045(18)30365-6","journal-title":"The Lancet Oncology"},{"issue":"25","key":"13084_CR9","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"Mark Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. (2017). https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"13084_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"T A Chan","year":"2018","unstructured":"Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann. Oncol. (2019). https:\/\/doi.org\/10.1093\/annonc\/mdy495","journal-title":"Annals of Oncology"},{"issue":"6230","key":"13084_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"Naiyer A. Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-.). (2015). https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"issue":"2","key":"13084_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"Robert M. Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. (2019). https:\/\/doi.org\/10.1038\/s41588-018-0312-8","journal-title":"Nature Genetics"},{"key":"13084_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research Network.","year":"2015","unstructured":"Cancer Genome Atlas Research Network. et al. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"13084_CR14","doi-asserted-by":"crossref","unstructured":"Angeles, A. K., Bauer, S., Ratz, L., Klauck, S. M. & S\u00fcltmann, H. Genome-based classification and therapy of prostate cancer. Diagnostics 8, pii: E62 (2018).","DOI":"10.3390\/diagnostics8030062"},{"key":"13084_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nature20788","volume":"541","author":"M Fraser","year":"2017","unstructured":"Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359\u2013364 (2017).","journal-title":"Nature"},{"issue":"15","key":"13084_CR16","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1158\/1078-0432.CCR-12-3606","volume":"19","author":"J. R. Schoenborn","year":"2013","unstructured":"Schoenborn, J. R., Nelson, P. & Fang, M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin. Cancer Res. (2013). https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3606","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"13084_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4161\/cbt.6.1.3489","volume":"6","author":"Robert K Nam","year":"2007","unstructured":"Nam, R. K. et al. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. (2007). https:\/\/doi.org\/10.4161\/cbt.6.1.3489","journal-title":"Cancer Biology & Therapy"},{"key":"13084_CR18","doi-asserted-by":"crossref","unstructured":"Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177\u2013188 (2008).","DOI":"10.1593\/neo.07822"},{"key":"13084_CR19","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"Y-M Wu","year":"2018","unstructured":"Wu, Y. -M. et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer article inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770\u20131782 (2018). e14.","journal-title":"Cell"},{"key":"13084_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","volume":"174","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433\u2013447 (2018). e19.","journal-title":"Cell"},{"key":"13084_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769 (2018). e9.","journal-title":"Cell"},{"key":"13084_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"13084_CR23","doi-asserted-by":"publisher","unstructured":"Taylor, R. A. et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat. Commun. (2017). https:\/\/doi.org\/10.1038\/ncomms13671","DOI":"10.1038\/ncomms13671"},{"issue":"18","key":"13084_CR24","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1158\/0008-5472.CAN-17-1083","volume":"77","author":"Helen Davies","year":"2017","unstructured":"Davies, H. et al. Whole-genome sequencing reveals breast cancers with mismatch repair deficiency. Cancer Res. (2017). https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1083","journal-title":"Cancer Research"},{"issue":"4","key":"13084_CR25","doi-asserted-by":"publisher","first-page":"1003-1013.e15","DOI":"10.1016\/j.cell.2018.03.029","volume":"173","author":"Shadrielle Melijah G. Espiritu","year":"2018","unstructured":"Espiritu, S. M. G. et al. The Evolutionary landscape of localized prostate cancers drives clinical aggression. Cell (2018). https:\/\/doi.org\/10.1016\/j.cell.2018.03.029","journal-title":"Cell"},{"key":"13084_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029\u20131041 (2017). e21.","journal-title":"Cell"},{"key":"13084_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"issue":"5","key":"13084_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"Joshua Armenia","year":"2018","unstructured":"Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. (2018). https:\/\/doi.org\/10.1038\/s41588-018-0078-z","journal-title":"Nature Genetics"},{"key":"13084_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"issue":"2","key":"13084_CR30","doi-asserted-by":"publisher","first-page":"422-432.e13","DOI":"10.1016\/j.cell.2018.05.037","volume":"174","author":"David Y. Takeda","year":"2018","unstructured":"Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell (2018). https:\/\/doi.org\/10.1016\/j.cell.2018.05.037","journal-title":"Cell"},{"key":"13084_CR31","doi-asserted-by":"publisher","unstructured":"Mazrooei, P. et al. Somatic mutations and risk-variants converge on Cis-regulatory elements to reveal the cancer driver transcription regulators in primary prostate tumors. SSRN Electron. J. (2018). https:\/\/doi.org\/10.2139\/ssrn.3245213","DOI":"10.2139\/ssrn.3245213"},{"key":"13084_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ccell.2018.06.008","volume":"34","author":"F Menghi","year":"2018","unstructured":"Menghi, F. et al. The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell 34, 197\u2013210 (2018). e5.","journal-title":"Cancer Cell"},{"key":"13084_CR33","doi-asserted-by":"crossref","unstructured":"Pritchard, C. C. et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 5, 4988 (2014).","DOI":"10.1038\/ncomms5988"},{"issue":"10","key":"13084_CR34","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/ng.3934","volume":"49","author":"Paz Polak","year":"2017","unstructured":"Polak, P. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet. (2017). https:\/\/doi.org\/10.1038\/ng.3934","journal-title":"Nature Genetics"},{"key":"13084_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120 (2016).","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"13084_CR36","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","volume":"29","author":"A R Hansen","year":"2018","unstructured":"Hansen, A. R. et al. Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study. Ann. Oncol. (2018). https:\/\/doi.org\/10.1093\/annonc\/mdy232","journal-title":"Annals of Oncology"},{"issue":"15_suppl","key":"13084_CR37","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1200\/JCO.2018.36.15_suppl.5007","volume":"36","author":"Johann S. De Bono","year":"2018","unstructured":"De Bono, J. S. et al. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. (2018). https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5007","journal-title":"Journal of Clinical Oncology"},{"key":"13084_CR38","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.neo.2014.09.001","volume":"16","author":"JR Prensner","year":"2014","unstructured":"Prensner, J. R. et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia 16, 900\u2013908 (2014).","journal-title":"Neoplasia"},{"key":"13084_CR39","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/0008-5472.CAN-13-3159","volume":"74","author":"JR Prensner","year":"2014","unstructured":"Prensner, J. R. et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 74, 1651\u20131660 (2014).","journal-title":"Cancer Res."},{"key":"13084_CR40","doi-asserted-by":"publisher","unstructured":"Priestley, P. et al. Pan-cancer whole genome analyses of metastatic solid tumors. bioRxiv 415133 (2018). https:\/\/doi.org\/10.1101\/415133","DOI":"10.1101\/415133"},{"key":"13084_CR41","unstructured":"Broad Institute. Picard tools. https:\/\/broadinstitute.github.io\/picard\/ (2016). Available at: https:\/\/broadinstitute.github.io\/picard\/%5Cn http:\/\/broadinstitute.github.io\/picard\/."},{"key":"13084_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"13084_CR43","doi-asserted-by":"crossref","first-page":"D762","DOI":"10.1093\/nar\/gkx1020","volume":"46","author":"J Casper","year":"2018","unstructured":"Casper, J. et al. The UCSC genome browser database: 2018 update. Nucleic Acids Res. 46, D762\u2013D769 (2018).","journal-title":"Nucleic Acids Res."},{"key":"13084_CR44","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes, S. A. et al. COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D777\u2013D783 (2017).","journal-title":"Nucleic Acids Res."},{"key":"13084_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0531-8","volume":"10","author":"D Tamborero","year":"2018","unstructured":"Tamborero, D. et al. Cancer genome interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 10, 25 (2018).","journal-title":"Genome Med."},{"key":"13084_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ng.3774","volume":"49","author":"M Griffith","year":"2017","unstructured":"Griffith, M. et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat. Genet. 49, 170\u2013174 (2017).","journal-title":"Nat. Genet."},{"key":"13084_CR47","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1101\/gr.135350.111","volume":"22","author":"J Harrow","year":"2012","unstructured":"Harrow, J. et al. GENCODE: The reference human genome annotation for the ENCODE project. Genome Res. 22, 1760\u20131774 (2012).","journal-title":"Genome Res."},{"key":"13084_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525 (2017).","journal-title":"Nat. Med."},{"key":"13084_CR49","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/bioinformatics\/btl289","volume":"22","author":"W Huber","year":"2006","unstructured":"Huber, W., Toedling, J. & Steinmetz, L. M. Transcript mapping with high-density oligonucleotide tiling arrays. Bioinformatics 22, 1963\u20131970 (2006).","journal-title":"Bioinformatics"},{"key":"13084_CR50","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1093\/bioinformatics\/btx346","volume":"33","author":"B Gel","year":"2017","unstructured":"Gel, B. & Serra, E. karyoploteR: an R\/Bioconductor package to plot customizable genomes displaying arbitrary data. Bioinformatics 33, 3088\u20133090 (2017).","journal-title":"Bioinformatics"},{"key":"13084_CR51","doi-asserted-by":"publisher","unstructured":"Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. MutationalPatterns: Comprehensive genome-wide analysis of mutational processes. Genome Med. (2018). https:\/\/doi.org\/10.1186\/s13073-018-0539-0","DOI":"10.1186\/s13073-018-0539-0"},{"key":"13084_CR52","doi-asserted-by":"crossref","unstructured":"Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 11, 367 (2010).","DOI":"10.1186\/1471-2105-11-367"},{"key":"13084_CR53","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-ciriano, I., Lee, J., Xi, R., Jain, D. & Jung, Y. L. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.\u00a0bioRxiv 333617 (2018).","DOI":"10.1101\/333617"},{"key":"13084_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i03","volume":"25","author":"M Hahsler","year":"2008","unstructured":"Hahsler, M., Hornik, K. & Buchta, C. Getting things in order: an introduction to the R Package seriation. J. Stat. Softw. 25, 1\u201327 (2008).","journal-title":"J. Stat. Softw."},{"key":"13084_CR55","series-title":"Statistics and Computing","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-21706-2","volume-title":"Modern Applied Statistics with S","author":"W. N. Venables","year":"2002","unstructured":"Venables, W. N. & Ripley, B. D. Modern Appl. Stat. S. (2002). https:\/\/doi.org\/10.1007\/978-0-387-21706-2"},{"issue":"1","key":"13084_CR56","doi-asserted-by":"publisher","first-page":"e201800115","DOI":"10.26508\/lsa.201800115","volume":"2","author":"Abhishek A Singh","year":"2018","unstructured":"Singh, A. A. Optimized ChIP-seq method facilitates transcription factor profiling in human tumors. Life Sci. Alliance\u00a02, e201800115 (2019).","journal-title":"Life Science Alliance"},{"issue":"1","key":"13084_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/1471-2164-14-232","volume":"14","author":"Wilbert Zwart","year":"2013","unstructured":"Zwart, W. et al. A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. BMC Genomics (2013). https:\/\/doi.org\/10.1186\/1471-2164-14-232","journal-title":"BMC Genomics"},{"key":"13084_CR58","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"issue":"9","key":"13084_CR59","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Yong Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biology"},{"key":"13084_CR60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nbt.2596","volume":"31","author":"V Kumar","year":"2013","unstructured":"Kumar, V. et al. Uniform, optimal signal processing of mapped deep-sequencing data. Nat. Biotechnol. 31, 615\u2013622 (2013).","journal-title":"Nat. Biotechnol."},{"key":"13084_CR61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/onc.2017.330","volume":"37","author":"S Stelloo","year":"2018","unstructured":"Stelloo, S. et al. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. Oncogene 37, 313\u2013322 (2018).","journal-title":"Oncogene"},{"key":"13084_CR62","doi-asserted-by":"publisher","unstructured":"Kim, S. et al. Strelka2: Fast and accurate variant calling for clinical sequencing applications. doi.org 192872 (2017). https:\/\/doi.org\/10.1101\/192872","DOI":"10.1101\/192872"},{"issue":"11","key":"13084_CR63","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1101\/gr.180281.114","volume":"24","author":"Gavin Ha","year":"2014","unstructured":"Ha, G. et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. (2014). https:\/\/doi.org\/10.1101\/gr.180281.114","journal-title":"Genome Research"},{"issue":"18","key":"13084_CR64","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T. Rausch","year":"2012","unstructured":"Rausch, T. et al. DELLY: Structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics (2012). https:\/\/doi.org\/10.1093\/bioinformatics\/bts378","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13084-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T21:04:51Z","timestamp":1671224691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13084"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13084-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/546051","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"24 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5251"}}